Obviousness

Here is an analysis of the obviousness of U.S. Patent No. 11,589,880 under 35 U.S.C. § 103, based on the provided prior art.

Obviousness Analysis under 35 U.S.C. § 103

Under United States patent law, an invention is considered obvious and therefore unpatentable if the differences between the invention and the prior art are such that the invention as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (PHOSITA). This analysis considers whether a PHOSITA would have been motivated to combine teachings from multiple prior art references to arrive at the claimed invention with a reasonable expectation of success.

The relevant PHOSITA for US 11,589,880 would be a medical device engineer or an interventional physician (such as an interventional cardiologist or radiologist, or a cardiovascular surgeon) with several years of experience in designing or performing endovascular procedures, particularly those involving catheter-based thrombectomy, embolectomy, and extracorporeal circuits as of the priority date of December 20, 2007.

Obviousness of Independent Claim 1

Independent Claim 1 recites a method for capturing undesirable biological material that becomes dislodged during a surgical procedure. This claim is likely obvious over the combination of a primary reference teaching the apparatus and its basic function, with secondary knowledge in the art regarding the risks of procedural embolization.

Primary Combination: U.S. Patent No. 6,245,088 (Fischell) in view of the known clinical problem of iatrogenic embolism.

1. Scope of the Prior Art:

   • Fischell et al. ('088): As established in the prior art analysis, Fischell teaches a complete system for removing occlusive material from blood vessels. It explicitly discloses a "first cannula" (aspiration catheter) with a deployable, self-expanding "funnel-shaped distal tip" (Fischell, Claim 1), a "second cannula" (venous return line), a pump, and a filter. The taught method involves aspirating blood and the occlusion, filtering the material, and reinfusing the blood to the patient. This system contains all the necessary hardware and performs all the core process steps of Claim 1 of the '880 patent. The only element not explicitly taught is the specific application—using the system prophylactically to capture material dislodged during a separate surgical action, rather than simply removing a pre-existing occlusion.

2. Motivation to Combine:

   • A PHOSITA would have been well aware that many surgical and interventional procedures carry a significant risk of dislodging biological material (thrombus, vegetations, tumor fragments, atheromatous debris), leading to potentially catastrophic embolic events like a stroke or pulmonary embolism. Procedures such as pacemaker lead extraction, cardiac valve repair, or even the manipulation of catheters in diseased vessels were known to carry this risk.
   • The motivation to apply the Fischell system to this known problem is straightforward and compelling: to improve patient safety. A PHOSITA, knowing of a system like Fischell's that is designed to safely remove large volumes of embolic material from the vasculature en bloc while preventing hemodynamic instability (via blood reinfusion), would see it as an obvious and logical step to use that same system as a protective measure.
   • Placing Fischell's device downstream from a surgical site where debris is expected to be generated is a predictable application of the technology. The goal of Fischell is to remove emboli; the goal in the '880 patent is to prevent the consequences of emboli generated during a procedure. A PHOSITA would have been motivated to combine the Fischell device with the known surgical problem to proactively capture the emboli at their source, thereby preventing them from traveling elsewhere. This would have been seen as a simple application of an existing tool to a known and analogous problem, with a high expectation of success.

Similar arguments can be made using Jolly et al. (US 2007/0112368) or Cragg et al. (US 2003/0088270) as the primary reference, as both also teach the core system of a funnel-tipped aspiration catheter with a blood reinfusion circuit.

Obviousness of Independent Claims 15 and 20

Independent Claims 15 and 20 are narrower, specifying the method for capturing "vegetative growth" dislodged during a "pacemaker lead removal." These claims are likely obvious over a primary reference teaching the apparatus, combined with a secondary reference establishing the specific, known danger of embolization during pacemaker lead extractions.

Primary Combination: U.S. Patent No. 6,245,088 (Fischell) in view of medical literature describing the risks of pacemaker lead extraction.

1. Scope of the Prior Art:

   • Fischell et al. ('088): As before, Fischell provides the system and method for large-volume aspiration with reinfusion using a funnel-tipped cannula. The system is designed for use in large vessels like the vena cava and right heart chambers—precisely where pacemaker leads are located and where vegetations would be dislodged.
   • Known Risk of Pacemaker Lead Extraction: It was well-established in the medical literature prior to 2007 that pacemaker leads could become infected and develop vegetations. Furthermore, the procedure to extract these leads carried a known, non-trivial risk of dislodging these vegetations, leading to septic pulmonary embolism, which has a high mortality rate. This was a widely discussed clinical challenge.

2. Motivation to Combine:

   • A PHOSITA, particularly a surgeon, faced with a high-risk lead extraction on a patient with known or suspected vegetations, would be actively seeking methods to mitigate the risk of pulmonary embolism.
   • Upon reviewing existing technologies, the system described by Fischell (or Jolly, or Cragg) would present an obvious solution. Fischell's device is designed to remove large, irregular pieces of biological material from the very anatomical locations where the danger exists. The motivation would be to position the Fischell device's funnel-shaped tip in the right ventricle or main pulmonary artery—immediately downstream from the lead being extracted—to create a "safety net."
   • Applying suction during the lead manipulation would predictably capture any large vegetations that break free before they can travel deep into the pulmonary circulation. This represents a direct application of Fischell's clot-capturing technology to capture an analogous material (vegetations) to prevent a known and specific procedural complication. A PHOSITA would have had every reason to combine the known tool (Fischell) with the known problem (embolism from lead extraction) and would have had a very high expectation that the combination would work as intended.

Therefore, Claims 15 and 20 appear to be an obvious application of a known thrombectomy system to a specific, well-documented surgical problem.